Skip to content
Home/Companies/Biotechnology/Atsena Therapeutics
Atsena Therapeutics

Atsena Therapeutics

Biotechnology·US·Active·6yr hold
Entry
2020
Hold
6yr
Status
Active

Who owns Atsena Therapeutics?

Atsena Therapeutics is currently owned by Abingworth through Abingworth Bioventures VII (2018 vintage), since 2020.

Hand-verified · updated 2026-06-07

Abingworth
Investor
Abingworth
Abingworth Bioventures VII · 2018 · Life Sciences VC

Key facts

HQUSA
SectorBiotechnology
StatusActive
Websiteatsenatx.com

More from Abingworth Bioventures VII

Other portfolio companies in the same fund.

Adicet Bio
Adicet Bio
Active
BiotechUS· 2021
Soteria Biotherapeutics
Soteria Biotherapeutics
Active
HealthcareUS· 2021
Orbus Therapeutics
Orbus Therapeutics
Active
HealthcareUS· 2020
Q32 Bio
Exited 2024
BiotechUS· 2020
Scorpion Therapeutics
Scorpion Therapeutics
Exited 2025
BiotechUS· 2020
to
Spruce Biosciences
Spruce Biosciences
Exited 2020
BiotechUS· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Atsena Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Atsena Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue